Equities Analysts Set Expectations for UNCY Q2 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - HC Wainwright issued their Q2 2025 EPS estimates for shares of Unicycive Therapeutics in a research note issued on Tuesday, May 27th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.08) per share for the quarter. HC Wainwright has a "Strong-Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics' Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.25) EPS, Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.29 EPS, Q3 2026 earnings at $0.37 EPS, FY2026 earnings at $1.41 EPS, FY2027 earnings at $2.89 EPS, FY2028 earnings at $2.75 EPS and FY2029 earnings at $2.06 EPS.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.09.

Separately, Guggenheim assumed coverage on Unicycive Therapeutics in a report on Monday, April 21st. They issued a "buy" rating and a $6.00 price objective on the stock.

Unicycive Therapeutics Price Performance

Unicycive Therapeutics stock traded up $0.02 during midday trading on Thursday, reaching $0.60. The company's stock had a trading volume of 751,917 shares, compared to its average volume of 956,367. The stock's 50-day simple moving average is $0.59 and its 200-day simple moving average is $0.62. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $0.96. The stock has a market capitalization of $72.86 million, a P/E ratio of -0.62 and a beta of 2.14.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Northern Trust Corp lifted its position in Unicycive Therapeutics by 142.4% during the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after acquiring an additional 34,183 shares during the period. XTX Topco Ltd boosted its stake in shares of Unicycive Therapeutics by 142.2% during the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after purchasing an additional 100,679 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after purchasing an additional 122,089 shares during the last quarter. Acuta Capital Partners LLC grew its position in shares of Unicycive Therapeutics by 16.4% in the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after purchasing an additional 323,801 shares during the period. Finally, Vivo Capital LLC grew its position in shares of Unicycive Therapeutics by 14.0% in the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company's stock valued at $6,537,000 after purchasing an additional 1,400,000 shares during the period. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.